MX2012002139A - Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. - Google Patents
Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.Info
- Publication number
- MX2012002139A MX2012002139A MX2012002139A MX2012002139A MX2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- cmet
- diagnosis
- prognosis
- disorders associated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 2
- 231100000590 oncogenic Toxicity 0.000 abstract 2
- 230000002246 oncogenic effect Effects 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23586409P | 2009-08-21 | 2009-08-21 | |
| EP09305777A EP2287197A1 (en) | 2009-08-21 | 2009-08-21 | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| US34800510P | 2010-05-25 | 2010-05-25 | |
| PCT/EP2010/062271 WO2011020925A1 (en) | 2009-08-21 | 2010-08-23 | Anti-cmet antibody and its use for the detection and the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002139A true MX2012002139A (es) | 2012-03-07 |
Family
ID=41571045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002139A MX2012002139A (es) | 2009-08-21 | 2010-08-23 | Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8673302B2 (enExample) |
| EP (2) | EP2287197A1 (enExample) |
| JP (1) | JP5951486B2 (enExample) |
| KR (1) | KR20120051734A (enExample) |
| CN (1) | CN102639564B (enExample) |
| AR (1) | AR077901A1 (enExample) |
| AU (1) | AU2010284944B2 (enExample) |
| BR (1) | BR112012003759A2 (enExample) |
| CA (1) | CA2769427C (enExample) |
| ES (1) | ES2692522T3 (enExample) |
| IL (1) | IL218202A (enExample) |
| IN (1) | IN2012DN01322A (enExample) |
| MX (1) | MX2012002139A (enExample) |
| NZ (2) | NZ598194A (enExample) |
| RU (1) | RU2582265C2 (enExample) |
| SG (1) | SG178339A1 (enExample) |
| TW (1) | TW201111781A (enExample) |
| WO (1) | WO2011020925A1 (enExample) |
| ZA (1) | ZA201202076B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| EP3264089A1 (en) | 2010-08-31 | 2018-01-03 | Genentech, Inc. | Biomarkers and methods of treatment |
| KR101444837B1 (ko) * | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| AU2012340826A1 (en) | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
| WO2013078145A1 (en) * | 2011-11-21 | 2013-05-30 | Taivex Therapeutics Corporation | Biomarkers for cancers responsive to modulators of hec1 activity |
| GB201121914D0 (en) | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Method for patient selection |
| EP2870178B1 (en) * | 2012-05-09 | 2017-07-12 | Eli Lilly and Company | Anti-c-met antibodies |
| WO2013192594A2 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind c-met |
| CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031626A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015032695A1 (en) * | 2013-09-09 | 2015-03-12 | Ventana Medical Systems, Inc. | Scoring method for mesothelin protein expression |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| EP3122900A1 (en) * | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| JP2017524371A (ja) | 2014-05-23 | 2017-08-31 | ジェネンテック， インコーポレイテッド | Ｍｉｔバイオマーカーとその使用方法 |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016124568A1 (en) * | 2015-02-03 | 2016-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-rho gtpase conformational single domain antibodies and uses thereof |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| DK3270965T3 (da) * | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
| ES2896709T3 (es) | 2016-02-05 | 2022-02-25 | Helixmith Co Ltd | Anticuerpos anti-c-Met y usos de los mismos |
| KR20230028574A (ko) | 2016-05-17 | 2023-02-28 | 애브비 바이오테라퓨틱스 인크. | 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| RU2735918C2 (ru) * | 2018-06-07 | 2020-11-10 | Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" | Набор реагентов для выявления маркера эпителиальных карцином |
| WO2020001526A1 (zh) * | 2018-06-29 | 2020-01-02 | 苏州智核生物医药科技有限公司 | Pd-l1结合多肽及其用途 |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| JP2022535880A (ja) * | 2019-06-06 | 2022-08-10 | アポロミクス インコーポレイテッド（ハンジョウ） | ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| CA3161919A1 (en) | 2020-09-01 | 2022-03-10 | Remegen Co., Ltd. | Anti-c-met antibody-drug conjugate and applications thereof |
| EP4210704A4 (en) * | 2020-09-08 | 2024-08-28 | Ideaya Biosciences, Inc. | PHARMACEUTICAL COMBINATION AND ANTITUMOR TREATMENT |
| AU2023283550A1 (en) * | 2022-06-09 | 2024-11-21 | Santa Ana Bio, Inc. | Antibodies targeting c-kit and/or siglec and uses thereof |
| MA71625A (fr) | 2022-07-30 | 2025-05-30 | Pinetree Therapeutics, Inc. | Compositions pour la dégradation lysosomale ciblée et leurs procédés d'utilisation |
| WO2025036355A1 (zh) * | 2023-08-14 | 2025-02-20 | 明慧医药（杭州）有限公司 | 抗c-MET纳米抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| CA2472383A1 (en) * | 2001-12-27 | 2003-07-17 | Van Andel Research Institute | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| WO2007056523A2 (en) * | 2005-11-08 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing and monitoring the progression of cancer |
| KR101429297B1 (ko) * | 2006-02-06 | 2014-08-12 | 메테레시스 트랜스레이셔날 리서치 에스.에이. | 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물 |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
-
2009
- 2009-08-21 EP EP09305777A patent/EP2287197A1/en not_active Withdrawn
-
2010
- 2010-08-23 IN IN1322DEN2012 patent/IN2012DN01322A/en unknown
- 2010-08-23 BR BR112012003759A patent/BR112012003759A2/pt not_active Application Discontinuation
- 2010-08-23 ES ES10744608.0T patent/ES2692522T3/es active Active
- 2010-08-23 JP JP2012525183A patent/JP5951486B2/ja active Active
- 2010-08-23 AU AU2010284944A patent/AU2010284944B2/en active Active
- 2010-08-23 WO PCT/EP2010/062271 patent/WO2011020925A1/en not_active Ceased
- 2010-08-23 NZ NZ598194A patent/NZ598194A/en unknown
- 2010-08-23 TW TW099128075A patent/TW201111781A/zh unknown
- 2010-08-23 NZ NZ700437A patent/NZ700437A/en unknown
- 2010-08-23 AR ARP100103069A patent/AR077901A1/es not_active Application Discontinuation
- 2010-08-23 US US13/391,435 patent/US8673302B2/en active Active
- 2010-08-23 MX MX2012002139A patent/MX2012002139A/es not_active Application Discontinuation
- 2010-08-23 RU RU2012109004/10A patent/RU2582265C2/ru active
- 2010-08-23 SG SG2012009106A patent/SG178339A1/en unknown
- 2010-08-23 KR KR1020127005757A patent/KR20120051734A/ko not_active Withdrawn
- 2010-08-23 EP EP10744608.0A patent/EP2467402B1/en active Active
- 2010-08-23 CA CA2769427A patent/CA2769427C/en active Active
- 2010-08-23 CN CN201080036635.7A patent/CN102639564B/zh active Active
-
2012
- 2012-02-19 IL IL218202A patent/IL218202A/en active IP Right Grant
- 2012-03-20 ZA ZA2012/02076A patent/ZA201202076B/en unknown
-
2014
- 2014-01-24 US US14/163,501 patent/US20140295452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2467402A1 (en) | 2012-06-27 |
| CN102639564A (zh) | 2012-08-15 |
| IL218202A (en) | 2017-07-31 |
| EP2287197A1 (en) | 2011-02-23 |
| RU2582265C2 (ru) | 2016-04-20 |
| ZA201202076B (en) | 2012-11-28 |
| NZ700437A (en) | 2016-04-29 |
| AU2010284944A1 (en) | 2012-03-08 |
| CA2769427A1 (en) | 2011-02-24 |
| IL218202A0 (en) | 2012-04-30 |
| AR077901A1 (es) | 2011-09-28 |
| NZ598194A (en) | 2015-05-29 |
| US20120149031A1 (en) | 2012-06-14 |
| WO2011020925A1 (en) | 2011-02-24 |
| JP2013502213A (ja) | 2013-01-24 |
| CN102639564B (zh) | 2015-01-07 |
| AU2010284944B2 (en) | 2016-01-28 |
| US8673302B2 (en) | 2014-03-18 |
| TW201111781A (en) | 2011-04-01 |
| KR20120051734A (ko) | 2012-05-22 |
| ES2692522T3 (es) | 2018-12-04 |
| RU2012109004A (ru) | 2013-09-27 |
| EP2467402B1 (en) | 2018-08-01 |
| BR112012003759A2 (pt) | 2017-07-11 |
| US20140295452A1 (en) | 2014-10-02 |
| JP5951486B2 (ja) | 2016-07-13 |
| SG178339A1 (en) | 2012-03-29 |
| IN2012DN01322A (enExample) | 2015-06-05 |
| CA2769427C (en) | 2020-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002139A (es) | Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. | |
| PH12012502466A1 (en) | Novel antibody for the diagnosis and/or prognosis of cancer | |
| ATE551073T1 (de) | Markierte hgf-bindende peptide für bildgebung | |
| GB0718967D0 (en) | Peptide imaging agents | |
| WO2011028698A3 (en) | Mri and optical assays for proteases | |
| MX2010000405A (es) | Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos. | |
| EP2502628A3 (en) | Polynucleotides and polypeptide sequences involved in cancer | |
| IL207637A (en) | Choosing a Breast Cancer Remedy Using Antibody-Based Arrays | |
| WO2012054638A3 (en) | Nmr systems and methods for the detection of analytes | |
| WO2010081001A3 (en) | Recurrent gene fusions in cancer | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| UA101167C2 (ru) | Фармацевтическая композиция, предназначенная для лечения глазной болезни | |
| WO2007080597A3 (en) | Polynucleotide and polypeptide sequences and methods for diagnosis | |
| NZ599707A (en) | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) | |
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| WO2014117680A3 (zh) | 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆 | |
| WO2007120311A3 (en) | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics | |
| WO2012006394A3 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
| WO2009148896A3 (en) | Anti-phospho-akt antibodies | |
| WO2012003493A3 (en) | Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use | |
| WO2011141153A8 (en) | Methods for the diagnosis and prognosis of a tumor using bcat1 protein | |
| WO2010144846A3 (en) | Gastrointestinal disease or disorder imaging and treatment | |
| MX2014008306A (es) | Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante. | |
| WO2010118324A3 (en) | Antibodies against fatty acid synthase | |
| WO2013188823A3 (en) | Cancer prognostic assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |